Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997607 | 0.91 | AOC3 (0.46) | AOC3DGAT1 | |
| SCHEMBL14136646 | 0.82 | AOC3 (0.46) | AOC3DGAT1 | |
| SCHEMBL16997608 | 0.79 | DGAT1 (0.46) | DGAT1ITGB3ITGA2B | |
| SCHEMBL17875325 | 0.75 | AOC3 (0.46) | AOC3DGAT1 | |
| SCHEMBL14061910 | 0.75 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL6834547 | 0.71 | AOC3 (0.61) | AOC3ITGB3ITGA2B | |
| SCHEMBL14136851 | 0.70 | DGAT1 (0.51) | DGAT1ITGB3ITGA2B | |
| SCHEMBL14136898 | 0.69 | AOC3 (0.48) | AOC3DGAT1ITGB3ITGA2B | |
| SCHEMBL14061622 | 0.68 | AOC3 (0.60) | AOC3ITGB3ITGA2B | |
| SCHEMBL29505381 | 0.68 | AOC3 (0.60) | AOC3ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225425-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150225425-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225425-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | AOC3 2375/4885MAPK1 1004/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.